Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 1,001–1,100 of 15,747
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age
Muñoz, F. M., Sher, L., Sabharwal, C., Gurtman, A., Xu, X., Kitchin, N. R. E., Lockhart, S. P., Riesenberg, R. A., Sexter, J. M., Czajka, H., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2211031 · Cited by 111
“, geometric mean ratios) 1 month after doses 2 and 3 among children 6 months to less than 2 years of age and children 2 to 4 years of age in phase 2–3 as compared with GMTs 1 month after dose 2 among persons 16 to 25 years of age from the pivotal trial.(10) Serum samples for each comparison were assayed in parallel to…”
BackgroundSelf-citationMultisystem inflammatory syndrome in an adult following the SARS-CoV-2 vaccine (MIS-V)
Nune, A., Iyengar, K. P., Goddard, C., & Ahmed, A. E. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-243888 · Cited by 99
The COVID-19 Pandemic: a Threat to Antimicrobial Resistance Containment
Founou, R. C., Blocker, A., Noubom, M., Tsayem, C., Choukem, S. P., van Dongen, M. B. M., & Founou, L. L. (2021) · Future Science OA · doi:10.2144/fsoa-2021-0012 · Cited by 108
“For instance, the BNT162b2 vaccine displays a 95% of vaccine efficacy [30].”
BackgroundGarcía‐Arriaza, J., Garaigorta, U., Pérez, P., Lázaro-Frías, A., Zamora, C., Gastaminza, P., del Fresno, C., Casasnovas, J. M., Sorzano, C. Ó. S., Sancho, D., et al. (2021) · Journal of Virology · doi:10.1128/jvi.02260-20 · Cited by 107
Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics
Kang, D. D., Li, H., & Dong, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114961 · Cited by 100
Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines
Long, B., Bridwell, R. E., & Gottlieb, M. A. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2021.05.054 · Cited by 102
Immunopeptidomics-based design of mRNA vaccine formulations against Listeria monocytogenes
Mayer, R. L., Verbeke, R., Asselman, C., Aernout, I., Gul, A., Eggermont, D., Boucher, K. L., Théry, F., Maia, T. M., Demol, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33721-y · Cited by 112
Chen, Z., Tian, Y., Yang, J., Wu, F., Liu, S., Cao, W., Xu, W., Hu, T., Siegwart, D. J., & Xiong, H. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c09143 · Cited by 113
Zhang, J., He, Q., An, C., Mao, Q., Gao, F., Bian, L., Xing, W., Wang, Q., Liu, P., Song, L., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1957401 · Cited by 100
Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape
Bushman, M., Kahn, R. J., Taylor, B. P., Lipsitch, M., & Hanage, W. P. (2021) · Cell · doi:10.1016/j.cell.2021.11.026 · Cited by 99
Lipid Nanoparticle Technologies for Nucleic Acid Delivery: A Nanoarchitectonics Perspective
Ferhan, A. R., Park, S.-H., Park, H., Tae, H., Jackman, J. A., & Cho, N. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202203669 · Cited by 104
Felten, R., Kawka, L., Dubois, M., Ugarte-Gil, M. F., Fuentes-Silva, Y., Piga, M., & Arnaud, L. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00221-6 · Cited by 105
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodiesPreprint
Planas, D., Bruel, T., Grzelak, L., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.12.430472 · Cited by 100
Hou, F., Zhang, Y., Liu, X., Murad, Y. M., Xu, J., Yu, Z., Hua, X., Song, Y., Ding, J., Huang, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41628-5 · Cited by 113
Benjamini, O., Rokach, L., Itchaki, G., Braester, A., Shvidel, L., Goldschmidt, N., Shapira, S., Dally, N., Avigdor, A., Rahav, G., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.279196 · Cited by 98
“in months (range) 66 (1-362) 97 (3-341) <10”
Teran, R. A., Walblay, K., Shane, E. L., Xydis, S. N., Gretsch, S. R., Gagner, A., Samala, U., Choi, H., Zelinski, C., & Black, S. R. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7017e1 · Cited by 99
Canaday, D. H., Carias, L. L., Oyebanji, O. A., Keresztesy, D., Wilk, D. J., Payne, M., Aung, H., Denis, K. S., Lam, E. C., Rowley, C. F., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab447 · Cited by 100
Frara, S., Allora, A., Castellino, L., di Filippo, L., Loli, P., & Giustina, A. (2021) · Pituitary · doi:10.1007/s11102-021-01148-1 · Cited by 112
Uptake of COVID-19 Vaccines among Pregnant Women: A Systematic Review and Meta-Analysis
Galanis, P., Vraka, I. S., Siskou, O. C., Konstantakopoulou, O., Katsiroumpa, A., & Καϊτελίδου, Δ. (2022) · Vaccines · doi:10.3390/vaccines10050766 · Cited by 113
Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review
Pooley, N., Karim, S. S. A., Combadière, B., Ooi, E. E., Harris, R. C., Guerche‐Séblain, C. E., Kisomi, M., & Shaikh, N. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00753-2 · Cited by 108
Pastorio, C., Zech, F., Noettger, S., Jung, C., Jacob, T., Sanderson, T., Sparrer, K. M. J., & Kirchhoff, F. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.07.006 · Cited by 100
“org/vaccines/6/), is frequently used in Europe and the US, and induces efficient protection against most COVID-19 variants (Polack et al., 2020) but shows about a 5- to 40-fold lower efficiency against Omicron (Cele et al.”
High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients
Longlune, N., Nogier, M. B., Miédougé, M., Gabilan, C., Cartou, C., Seigneuric, B., Bello, A. D., Marion, O., Faguer, S., Izopet, J., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab193 · Cited by 106
Marquez, C., Kerkhoff, A. D., Naso, J., Contreras, M. G., Diaz, E. C., Rojas, S., Peng, J., Rubio, L., Jones, D., Jacobo, J., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257111 · Cited by 110
Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples
Bates, T. A., Leier, H. C., Lyski, Z. L., Goodman, J. R., Curlin, M. E., Messer, W. B., & Tafesse, F. G. (2021) · JAMA · doi:10.1001/jama.2021.11656 · Cited by 99
Chodcik, G., Tene, L., Patalon, T., Gazit, S., Ben-Tov, A., Cohen, D., & Muhsen, K. (2021) · medRxiv · doi:10.1101/2021.01.27.21250612 · Cited by 95
Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
Xia, H., Zou, J., Kurhade, C., Cai, H., Yang, Q., Cutler, M., Cooper, D., Muik, A., Jansen, K. U., Xie, X., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.02.015 · Cited by 97
“We thank the Pfizer-BioNTech clinical trial C4591001 and NCT04368728 participants from whom the post-immunization human sera were obtained.”
InfluentialSelf-citationEffectiveness of the Coronavirus Disease 2019 Bivalent Vaccine
Shrestha, N. K. M., Burke, P. C., Nowacki, A. S., Simon, J. F., Hagen, A. E. F., & Gordon, S. M. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad209 · Cited by 98
Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant
Khan, K., Lustig, G., Roemer, C., Reedoy, K., Jule, Z., Karim, F., Ganga, Y., Bernstein, M. P., Baig, Z., Jackson, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43703-3 · Cited by 98
Simonsen, J. B. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.04.022 · Cited by 120
Previous COVID-19 Infection and Antibody Levels After Vaccination
Ali, H., Alahmad, B., Al‐Shammari, A. A., Alterki, A., Hammad, M. M., Cherian, P., Al‐Khairi, I., Sindhu, S. T. A. K., Thanaraj, T. A., Mohammad, A., et al. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.778243 · Cited by 105
Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose
Lustig, Y., Gonen, T., Meltzer, L., Gilboa, M., Indenbaum, V., Cohen, C., Amit, S., Jaber, H., Doolman, R., Asraf, K., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01212-3 · Cited by 100
SARS-CoV-2 genomics: An Indian perspective on sequencing viral variants
Srivastava, S., Banu, S., Singh, P., Sowpati, D. T., & Mishra, R. K. (2021) · Journal of Biosciences · doi:10.1007/s12038-021-00145-7 · Cited by 101
Ghione, P., Gu, J. J., Attwood, K. M., Torka, P., Goel, S., Sundaram, S., Mavis, C. K., Johnson, M. W., Thomas, R., McWhite, K., et al. (2021) · Blood · doi:10.1182/blood.2021012443 · Cited by 105
Wu, Z., & Li, T. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03015-x · Cited by 99
Cellular and biophysical barriers to lipid nanoparticle mediated delivery of RNA to the cytosol
Johansson, J. M., Rietz, H. D., Hedlund, H., Eriksson, H. C., Blenke, E. O., Pote, A. R., Harun, S., Nordenfelt, P., Lindfors, L., & Wittrup, A. (2025) · Nature Communications · doi:10.1038/s41467-025-60959-z · Cited by 142
“Several different nucleic acid-based therapeutics, including antisense 1 , siRNA 2,3 , and mRNA-compounds 4,5 have recently entered clinical use in diverse clinical settings.”
Gelfand, J. M., Armstrong, A. W., Bell, S. J., Anesi, G. L., Blauvelt, A., Calabrese, C. M., Dommasch, E. D., Feldman, S. R., Gladman, D. D., Kircik, L., et al. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.12.058 · Cited by 108
Stamatatos, L., Czartoski, J., Wan, Y.-H., Homad, L. J., Rubin, V., Glantz, H., Neradilek, M., Seydoux, E., Jennewein, M. F., MacCamy, A. J., et al. (2021) · doi:10.1101/2021.02.05.21251182 · Cited by 559
COVID-19 vaccination and breakthrough infections in patients with cancer
Schmidt, A. L., Labaki, C., Hsu, C., Bakouny, Z., Balanchivadze, N., Berg, S. A., Blau, S. H., Daher, A., Zarif, T. E., Friese, C. R., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.12.006 · Cited by 101
Ali, M., & Hossain, A. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-050303 · Cited by 106
Song, J. Y., Choi, W. S., Heo, J. Y., Lee, J. S., Jung, D. S., Kim, S.-W., Park, K.-H., Eom, J. S., Jeong, S. J., Lee, J., et al. (2022) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101569 · Cited by 96
Incidence of Bell Palsy in Patients With COVID-19
Tamaki, A., Cabrera, C. I., Li, S., Rabbani, C., Thuener, J. E., Rezaee, R. P., & Fowler, N. (2021) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2021.1266 · Cited by 98
Functional Role of miR-155 in the Pathogenesis of Diabetes Mellitus and Its Complications
Jankauskas, S. S., Gambardella, J., Sardu, C., Lombardi, A., & Santulli, G. (2021) · Non-Coding RNA · doi:10.3390/ncrna7030039 · Cited by 113
Reported orofacial adverse effects of COVID‐19 vaccines: The knowns and the unknowns
Cirillo, N. (2021) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.13165 · Cited by 99
Stabilized coronavirus spike stem elicits a broadly protective antibody
Hsieh, C., Werner, A. P., Leist, S. R., Stevens, L. J., Falconer, E., Goldsmith, J. A., Chou, C., Abiona, O. M., West, A., Westendorf, K., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109929 · Cited by 95
“In particular, mRNA-1273 and BNT162b2 showed >94% efficacy against COVID-19 in adult phase III clinical trials (Baden et al., 2020; Polack et al., 2020).”
Advances in gene-based vaccine platforms to address the COVID-19 pandemic
Pushparajah, D., Jimenez, S., Wong, S. L., Alattas, H., Nafissi, N., & Slavcev, R. A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.003 · Cited by 104
Chakraborty, C., Bhattacharya, M., & Dhama, K. (2023) · Vaccines · doi:10.3390/vaccines11030682 · Cited by 125
“Nucleosidemodified mRNA Germany, USA −70 ± 10 Two doses given three weeks apart [38]”
BackgroundThe European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines
Cavaleri, M., Enzmann, H., Straus, S., & Cooke, E. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00085-4 · Cited by 98
Spitzer, A., Angel, Y., Marudi, O., Zeltser, D., Saiag, E., Goldshmidt, H., Goldiner, I., Stark, M., Halutz, O., Gamzu, R., et al. (2022) · JAMA · doi:10.1001/jama.2021.23641 · Cited by 101
Current and future nanoparticle vaccines for COVID-19
Vu, M. N., Kelly, H. G., Kent, S. J., & Wheatley, A. K. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103699 · Cited by 107
“Both mRNA and lipid particles contain potent immunostimulatory properties [28,29], negating the need for additional formulation with adjuvants [3,4].”
Lehman, C. D., D’Alessandro, H. A., Mendoza, D. P., Succi, M. D., Kambadakone, A. R., & Lamb, L. R. (2021) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2021.03.001 · Cited by 95
Survey of symptoms following COVID-19 vaccination in IndiaPreprint
Jayadevan, R., Shenoy, R., & Anithadevi, T. S. (2021) · medRxiv · doi:10.1101/2021.02.08.21251366 · Cited by 98
Khalid, K., & Poh, C. L. (2023) · Vaccines · doi:10.3390/vaccines11071264 · Cited by 119
Garg, I., Shekhar, R., Sheikh, A. B., & Pal, S. (2021) · Infectious Disease Reports · doi:10.3390/idr13030064 · Cited by 113
“Both of these FDA-approved mRNA vaccines have shown robust immune response and protection against severe COVID-19 [38,39].”
BackgroundAdverse events following COVID-19 vaccination: A systematic review and meta-analysis
Kouhpayeh, H., & Ansari, H. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108906 · Cited by 110
“Very few and sporadic cases of Bell’s palsy following immunization with mRNA vaccines (Pfizer-BioNtech and Moderna) were also reported in clinical trials [18,46].”
InfluentialBNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants
Liu, Y., Liu, J., Xia, H., Zhang, X., Zou, J., Fontes-Garfias, C. R., Weaver, S. C., Swanson, K. A., Cai, H., Sarkar, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2106083 · Cited by 95
Self-citationExosomal mRNAs for Angiogenic–Osteogenic Coupled Bone Repair
Ma, Y., Sun, L., Zhang, J., Chiang, C., Pan, J., Wang, X., Kwak, K. J., Li, H., Zhao, R., Rima, X. Y., et al. (2023) · Advanced Science · doi:10.1002/advs.202302622 · Cited by 109
Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19
Bautista García, J., Peña Ortega, P., Bonilla Fernández, J. A., Cárdenes León, A., Ramírez Burgos, L., & Caballero Dorta, E. (2021) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2021.04.005 · Cited by 97
“05%).(5) Various authors have described a possible association between SARS-CoV-2 infection and the onset of autoimmune diseases via a mechanism of molecular mimicry and crossreaction.”
Jeremijenko, A., Chemaitelly, H., Ayoub, H. H., Alishaq, M., Abou-Samra, A.-B., Al Ajmi, J. A. A. A., Al Ansari, N. A. A., Al Kanaani, Z., Al Khal, A., Al Kuwari, E., et al. (2021) · Emerging Infectious Diseases · doi:10.3201/eid2705.204365 · Cited by 97
Guo, Y., Huang, L., Zhang, G., Yao, Y., Zhou, H., Shen, S., Shen, B., Li, B., Li, X., Zhang, Q., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22926-2 · Cited by 94
Mentzer, A. J., O’Connor, D., Bibi, S., Chelysheva, I., Clutterbuck, E., Demissie, T. M., Dinesh, T., Edwards, N. J., Felle, S., Feng, S., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02078-6 · Cited by 112
Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays
Sholukh, A. M., Fiore-Gartland, A. J., Ford, E. S., Miner, M. D., Hou, Y. J., Tse, L. V., Kaiser, H., Zhu, H., Lu, J., Madarampalli, B., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00527-21 · Cited by 123
Wang, J., Hou, Z., Liu, J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.04.026 · Cited by 96
“6% (196) of 30,351 participants in the mRNA-1273 COVID-19 vaccine trial.(4,5) Similar to the general population, side effects related to the COVID-19 vaccine in patients with NAFLD were mild and self-limiting, and no serious adverse events were reported.”
Flare of rheumatoid arthritis after COVID-19 vaccination
Terracina, K. A., & Tan, F. K. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00108-9 · Cited by 96
Lin, S., Kennedy, N. A., Saifuddin, A., Sandoval, D. M., Reynolds, C. J., Seoane, R. C., Kottoor, S. H., Pieper, F. P., Lin, K., Butler, D. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28517-z · Cited by 108
Tortorici, M. A., Walls, A. C., Joshi, A., Park, Y., Eguia, R. T., Miranda, M. C., Kepl, E., Dosey, A. M., Stevens‐Ayers, T., Boeckh, M. J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.05.019 · Cited by 95
“Since the coronavirus S glycoprotein is the target of neutralizing antibodies, it is the main focus of therapeutics and vaccine development, including monoclonal antibody therapies and vaccines (Baum et al., 2020; Corbett et al., 2020; Corti et al., 2021; Hansen et al., 2020; McCallum et al., 2021a; Piccoli et al., 20…”
Demonbreun, A. R., Sancilio, A., Velez, M. P., Ryan, D. T., Saber, R., Vaught, L. A., Reiser, N. L., Hsieh, R. R., D’Aquila, R. T., Mustanski, B. S., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101018 · Cited by 104
Brumme, Z. L., Mwimanzi, F. M., Lapointe, H. R., Cheung, P. K., Sang, Y., Duncan, M. C., Yaseen, F., Agafitei, O., Ennis, S., Ng, K., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00452-6 · Cited by 118
Shenai, M. B., Rahme, R., & Noorchashm, H. (2021) · Cureus · doi:10.7759/cureus.19102 · Cited by 110
“The overall risk of severe adverse effects is generally considered to be extremely low [1-3].”
BackgroundThe advent of clinical self-amplifying RNA vaccines
Casmil, I. C., Jin, J., Won, E.-J., Huang, C., Liao, S., Cha‐Molstad, H., & Blakney, A. K. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.060 · Cited by 124
Korang, S. K., von Rohden, E., Veroniki, A. A., Ong, G., Ngalamika, O., Siddiqui, F., Juul, S., Nielsen, E. E., Feinberg, J. B., Petersen, J. J., et al. (2022) · PLOS ONE · doi:10.1371/journal.pone.0260733 · Cited by 95
“The included vaccines were based on mRNA [34, 41, 42, 66]; viral vectors [37, 39, 43, 45, 47, 50, 52, 67]; protein-subunit [38, 53]; or inactivated virus [47–49, 51] (Table 5).”
BackgroundSingle-cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine
Sureshchandra, S., Lewis, S. A., Doratt, B. M., Jankeel, A., Coimbra Ibraim, I., & Messaoudi, I. (2021) · JCI Insight · doi:10.1172/jci.insight.153201 · Cited by 91
“Findings from human trials of Pfizer/BioNTech and Moderna suggest 95% maximal protection within 1-2 months after the second vaccine dose, including against several circulating variants of concern (9, 10).”
MethodHall, V, Foulkes, S., Charlett, A., Atti, A., Monk, E., Simmons, R., Wellington, E., Cole, M., Saei, A., Oguti, B., et al. (2021) · medRxiv · doi:10.1101/2021.01.13.21249642 · Cited by 96
Peeters, M., Verbruggen, L., Teuwen, L.-A. M. N., Vanhoutte, G., Kerckhove, S. V., Peeters, B., Raats, S., der Massen, I. V., Keersmaecker, S. D., Debie, Y., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100274 · Cited by 91
“However, ongoing antineoplastic treatment with cytotoxic drugs was an exclusion criterion in the pivotal phase III trial.(14) Hence, it remains unclear how antineoplastic treatment affects patient’s ability to mount protective immunity after BNT162b2 vaccination(15-17) and data regarding the safety of BNT162b2 vaccina…”
InfluentialBeladiya, J., Kumar, A., Vasava, Y., Parmar, K., Patel, D., Patel, S., Dholakia, S., Sheth, D., Boddu, S. H. S., & Patel, C. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.2507 · Cited by 96
“The studies of RNA ‐ based vaccines have 2 studies of BNT162b2 mRNA BioNTeach/Pfizer 19,22 and 1 study of mRNA ‐ 1273 Moderna.”
BackgroundInfluential‘Passive’ nanoparticles for organ-selective systemic delivery: design, mechanism and perspective
Fu, L., Zhang, Y., Farokhzad, R. A., Mendes, B. B., Conde, J., & Shi, J. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00998f · Cited by 106
Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV
Vergori, A., Cozzi‐Lepri, A., Cicalini, S., Matusali, G., Bordoni, V., Lanini, S., Meschi, S., Iannazzo, R., Mazzotta, V., Colavita, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32263-7 · Cited by 101
Small non-coding RNA therapeutics for cardiovascular disease
Shah, A. M., & Giacca, M. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac463 · Cited by 100
Lee, L. Y. W., Starkey, T., Ionescu, M. C., Little, M., Tilby, M., Tripathy, A. R., McKenzie, H., Hajji, Y. A., Barnard, M., Benny, L., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00202-9 · Cited by 100
Liu, Q. L., Huang, Y., Li, Z., Li, L., Zhao, Y., & Li, M. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202214230 · Cited by 113
Edelman-Klapper, H., Zittan, E., Shitrit, A. B., Rabinowitz, K. M., Goren, I., Avni‐Biron, I., Ollech, J. E., Lichtenstein, L., Banai-Eran, H., Yanai, H. A., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.10.029 · Cited by 103
“Patients with immune-mediated diseases such as inflammatory bowel diseases (IBD), both Crohn’s disease (CD) and ulcerative colitis (UC), were specifically excluded from trials.(2,3) These patients are often treated with immunomodulators and/or biologic therapy such as anti–tumor necrosis factor (TNF) a, potentially as…”
The importance of non-pharmaceutical interventions during the COVID-19 vaccine rollout
Gozzi, N., Bajardi, P., & Perra, N. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009346 · Cited by 98
A Combinatorial Library of Lipid Nanoparticles for Cell Type‐Specific mRNA Delivery
Naidu, G. S., Yong, S., Ramishetti, S., Rampado, R., Sharma, P., Ezra, A., Goldsmith, M., Hazan‐Halevy, I., Chatterjee, S., Aitha, A., et al. (2023) · Advanced Science · doi:10.1002/advs.202301929 · Cited by 109
COVID-19 and the Endocrine System: A Comprehensive Review on the Theme
Lisco, G., Tullio, A. D., Stragapede, A., Solimando, A. G., Albanese, F., Capobianco, M., Giagulli, V. A., Guastamacchia, E., Pergola, G. D., Vacca, A., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132920 · Cited by 110
Meslé, M. M. I., Brown, J., Mook, P., Katz, M. A., Hagan, J., Pastore, R., Benka, B., Redlberger‐Fritz, M., Bossuyt, N., Stouten, V., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00179-6 · Cited by 153
Larson, V. A., Seidenberg, R., Caplan, A. S., Brinster, N. K., Meehan, S. A., & Kim, R. H. (2021) · Journal of Cutaneous Pathology · doi:10.1111/cup.14104 · Cited by 94
“The BNT162b2 vaccine by Pfizer-BioNTech and mRNA-1273 vaccine by Moderna utilize mRNA encoded for the SARS-CoV-2 full-length spike protein that is encapsulated in lipid nanoparticle for delivery.(4,5) F IGURE 3 Eczematous reactions.”
MethodCOVID-19 in People Living with HIV: A Systematic Review and Meta-Analysis
Lee, K. W., Yap, S. F., Ngeow, Y. F., & Lye, M. S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18073554 · Cited by 96
VanBlargan, L. A., Adams, L. J., Liu, Z., Chen, R. E., Gilchuk, P., Raju, S., Smith, B. K., Zhao, H., Case, J. B., Winkler, E. S., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.016 · Cited by 94
Swift, M. D., Breeher, L. E., Tande, A. J., Tommaso, C. P., Hainy, C. M., Chu, H., Murad, M. H., Berbari, E. F., & Virk, A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab361 · Cited by 94
“By midDecember, two mRNA vaccines had received emergency use authorization (EUA) by the Food and Drug Administration (FDA), both of which demonstrated approximately 95% efficacy against symptomatic COVID-19 in clinical trials (3, 4).”
Zhang, C., Ma, Y., Zhang, J., Kuo, J. C., Zhang, Z., Xie, H., Zhu, J., & Liu, T. (2022) · Molecules · doi:10.3390/molecules27061943 · Cited by 108
“At the same time, BNT162b2, the Pfizer/BioNTech vaccine, has passed the clinical trial with 43,548 individuals with a 95% clinical efficacy in preventing COVID-19 illness, and the safety and anti-SARS-CoV-2 immune responses were also demonstrated [283,284].”
Kafetzis, K. N., Papalamprou, N., McNulty, E., Thong, K. X., Sato, Y., Mironov, A., Purohit, A., Welsby, P. J., Harashima, H., Yu‐Wai‐Man, C., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202203022 · Cited by 103
D’Agostino, V., Caranci, F., Negro, A., Piscitelli, V., Tuccillo, B., Fasano, F., Sirabella, G., Marano, I., Granata, V., Grassi, R., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11040285 · Cited by 102
Martínez-Mármol, R., Giordano-Santini, R., Kaulich, E., Cho, A.-N., Przybyla, M., Riyadh, M. A., Robinson, E., Chew, K. Y., Amor, R., Meunier, F. A., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg2248 · Cited by 94
Rane, M. S., Kochhar, S., Poehlein, E., You, W., Robertson, M. M., Zimba, R., Westmoreland, D. A., Romo, M. L., Kulkarni, S., Chang, M., et al. (2021) · American Journal of Epidemiology · doi:10.1093/aje/kwab293 · Cited by 108
“, New York, NY, USA and BioNTech, Mainz, Germany) (2) is fully approved for adults, while the Moderna mRNA-1273 (ModernaTX, Inc.”
BackgroundDoes a humoral correlate of protection exist for SARS-CoV-2? A systematic review
Perry, J. A., Osman, S., Wright, J., Richard‐Greenblatt, M., Buchan, S. A., Sadarangani, M., & Bolotin, S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266852 · Cited by 97
McNamara, L., Wiegand, R., Burke, R., Sharma, A. J., Sheppard, M., Adjemian, J., Ahmad, F. B., Anderson, R. N., Barbour, K. E., Binder, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02226-1 · Cited by 82
Weaver, K. N., Zhang, X., Dai, X., Watkins, R. D., Adler, J., Dubinsky, M. C., Kastl, A., Bousvaros, A., Strople, J. A., Cross, R. K., et al. (2021) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab302 · Cited by 93
Yang, J., Zhu, J., Sun, J., Chen, Y., Du, Y., Tan, Y., Wu, L., Zhai, M., Wei, L., Li, N., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.09.010 · Cited by 100
“1 The COVID-19 mRNA vaccine developed by BioNTech conferred an excellent rate of protection, preventing infection from COVID-19.”
Wang, S., Li, W., Wang, Z., Yang, W., Li, E., Xia, X., Yan, F., & Chiu, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01917-x · Cited by 143
Coburn, S. B., Humes, E., Lang, R., Stewart, C., Hogan, B., Gebo, K. A., Napravnik, S., Edwards, J. K., Browne, L., Park, L. S., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.15934 · Cited by 102
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.